Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A
Status:
Completed
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
This open-label, single-arm study will evaluate the safety of rituximab subcutaneously (SC)
administered during first line treatment for follicular non-Hodgkin's lymphoma (NHL)
(Induction and/or Maintenance treatment plus 24 months of follow up), or diffuse large B-cell
lymphoma (DLBCL) (treatment plus 24 months of follow-up).